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Objectives Limited population data on fatty liver disease (FLD) in Caucasians have been 
published. The main aim of the present study was to determine FLD prevalence and its 
association with cardiovascular disease risk in the general population of East Anglia using 
the Fenland Study. 
Design Population based study, with cross-sectional results.  
Setting 3 research centers in Cambridgeshire. 
Participants People registered at surgeries in Cambridgeshire aged 30 to 58, excluding 
participants with known diabetes mellitus, terminal illness or inability to walk unaided, and 
(possible) pregnancy.  
Measurements Participants underwent abdominal ultrasonography, anthropometric 
measurements, and blood (aminotransferases a.o.) and urine analysis was performed. 
Additionally participants filled in several questionnaires. 
Main outcome measures Liver fat by ultrasound scored in a cumulative fashion, several 
anthropometric measures, metabolic syndrome (ATP ΙΙΙ, IDF, and cumulative Z-score), and 
the 10-year Framingham risk score. 
Results Liver fat scores were obtained in 762 participants. Overall prevalence of FLD and 
non-alcoholic FLD (NAFLD) was 38.5% and 30.5%, respectively. FLD was more prevalent 
in men than women (p<0.001). By multiple logistic regression analysis on the presence of 
FLD, only BMI (p<0.05, OR 1.3) was significantly associated in men, and BMI (p<0.001, 
OR 1.6), waist circumference (p<0.01, OR 1.1), and hip circumference (p<0.01, OR .9) 
were significantly associated in women. With increasing liver fat category, the number of 
metabolic syndrome components (p<0.001 both ATP III and IDF), the cumulative Z-score 
(p<0.001) and the 10-year Framingham risk score (p<0.001) increased as well. 
Conclusions This study shows a striking prevalence of FLD in East Anglia, particularly in 
men. As FLD is associated with several CVD risk estimates, this striking prevalence may 
delineate an increased CVD risk in this population.      
 




Excessive accumulation of fat within hepatocytes results in a wide progressive spectrum 
usually referred to as fatty liver disease (FLD) 1. FLD is characterized by several 
histological changes which can roughly be divided into steatosis (fat accumulation) and 
steatohepatitis (fat accumulation with inflammation, with or without fibrosis) 2. As 
alcoholism is a well know risk factor for FLD, alcoholic FLD (AFLD) and non-alcoholic 
FLD (NAFLD) are often discriminated using an ethanol value of 20 g/d (140 g/w) 3. FLD, 
at least NAFLD, is associated with an increase in (liver-derived) CVD risk markers 3, 4. 
Additionally, FLD increases the risk for cirrhosis 5 and likely hepatocarcinoma as well 6, 7.  
In epidemiological studies, FLD is usually estimated by serum markers, i.e. the 
aminotransferases alanine aminotransferase (ALT) and/or gamma-glutamyl 
aminotransferase (GGT). When an elevation of systemic aminotransferases cannot be 
explained by the presence of other liver diseases, FLD is generally suspected. However, 
ALT isoforms 8, 9 and GGT isoforms 10, 11 are produced and present in numerous organs, 
and could therefore reflect pathology other than liver pathology, e.g. neuromuscular 
pathology 12. Therefore, sensitivity and specificity of aminotransferases for diagnosing FLD 
are questionable 13-17. In the relatively low ALT range, the entire histologic NAFLD 
spectrum, including non-alcoholic steatohepatitis (NASH) with advanced fibrosis, can be 
seen 13-15. In steatohepatitis, aminotransferase levels might even be lower compared to 
steatosis 16, 17. Of morbidly obese patients with steatohepatitis, 46% present with ALT ≤40 
U/L 14. In addition to aminotransferases, data on insulin resistance or diabetes may be 
needed in order to improve prediction of NAFLD 15. 
Currently, five Western general population-based studies on FLD using imaging modalities 
have been performed. These are the Dionysos Nutrition and Liver Study (DNLS) 18, 19, the 
Study of Health in Pomerania (SHIP) 20, the Dallas Heart Study (DHS) 21, 22, the Study on 
Echinococcus Multilocularis and Internal Diseases in Leutkirch (EMIL) 23, and the Finnish 
prevention program for type 2 diabetes (FIN-D2D) 24. These studies used ultrasonography 
18-20, 23 and magnetic resonance spectroscopy 21
, 22, 24, and revealed a FLD prevalence of 
approximately 30%, in the years 1997 – 2002 20-23. No general population based study on 
FLD has been performed in the United Kingdom (UK). Objectives of the current study 
were to: (i) estimate the prevalence of FLD and NAFLD in a UK population, and (ii) 
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investigate the association of FLD and aminotransferases, with metabolic CVD risk 











Figure І. Schematic display of the study area, including the three research centres  










The Fenland Study is an ongoing population-based cross-sectional study of 10,000 men and 
women born within the years 1950 – 1975 and resident in Cambridgeshire, UK (figure І) at 
the time of study recruitment. All individuals born within this birth cohort and registered at 
family doctor practices in Cambridgeshire were eligible for inclusion. Exclusion criteria 
were a known history of diabetes, terminal illness or the inability to walk unaided, and 
pregnant women were also excluded. The aim of the study is to examine the interactions 
between lifestyle and genetic factors on the risk of obesity and related quantitative 
metabolic traits. The study commenced in 2005 and aims to complete by 2014. 
 
STUDY POPULATION 
The present study includes Fenland study data, collected in the period 24 January 2005 to 
15 August 2008. In this period 3843 people participated in any measurement. Liver scans 
were not scored at the same rate as the rest of the data collection, which has caused a major 
back log. Particularly this back log, and possibly also some difficulties in scanning obese 
people 25
, 26, has caused 762 participants with liver fat scores and 3081 participants without 
liver fat scores. Percentage of females was 58.2% versus 53.4% (p<0.05), age was 45.7 
(±7.0) year versus 45.7 (±7.2) year (p=ns), BMI was 25.4 (17.3–49.4) versus 26.6 (16.9–
63.5) kg/m2 (p<0.001), and alcohol units per week were 5 (0 – 67) versus 4.5 (0–100) 
(p=ns), for the population with and without liver fat scores, respectively. 
 
DATA COLLECTION 
Data collected during the visit to the research facility 
The participants underwent several measurements during a single visit of three hours to a 
research facility, after an overnight fast. The research staff received systematic training 
prior to measurements.  
Anthropometry 
Participants were measured in barefoot wearing light clothing. Collected anthropometric 
data included weight (to the nearest 200 g, using a calibrated electronic scale; TANITA 
model BC-418 MA), height (to the nearest 0.1 cm, using a wall-mounted stadiometer; 
SECA 240, Birmingham, UK), and waist circumference and hip circumference (both to the 
Chapter 2. 
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nearest 0.1 cm using a non-stretchable fibre-glass insertion tape; D loop tape, Chasmors 
Ltd, UK). Waist circumference was measured midway between the lower rib margin and 
iliac crest. Hip circumference was measured as the widest level over the major trochanters.  
Biochemistry analysis of venous blood  
ALT and GGT were divided into quintiles based upon the total population. ALT and GGT 
cut-off values were both retrieved from the literature if available 27 and determined in the 
present study as well. Optimum cut-off values were established by adding up sensitivity 
and specificity. The aminotransferase value corresponding with the highest sum was 
considered the overall optimal cut-off value.   
Ultrasound imaging 
Hepatic ultrasonography was performed using a LOGIQ Book XP ultrasound system with a 
3C-RS curved transducer; GE Healthcare Bedford, UK. Four different sweeps (cine-loops) 
encompassing the entire liver were recorded: (1) starting at the right lobe in a longitudinal 
scan plane a sweep from lateral to medial was made, i.e. showing the liver and long axis of 
the right kidney, (2) starting at the dome of the right liver lobe in a transversal/oblique scan 
plane a sweep from cranial to caudal was made, i.e. showing the hepatic veins, the portal 
and gallbladder, (3) starting at the left lobe in a longitudinal scan plane a sweep from lateral 
to medial over the gall bladder area was made, and (4) starting at the left lobe in a 
transverse scan plane a sweep from cranial to caudal was made, i.e. showing the hepatic 
veins and pancreas. In a small part of participants scans with an acceptable quality could 
not be established, and were therefore excluded. 
Ultrasound scoring criteria and allocation of scores 
The recorded cine-loops were scored retrospectively by two operators, who received both 
theoretical and practical training from a senior radiographer. Liver fat scoring criteria were: 
(i) increased echo reflectivity of liver parenchyma, (ii) decreased visualization of intra-
hepatic vasculature, (iii) attenuation of ultrasound beam. Each criterion was scored on 4-
point scale (i.e. as 1, 2, 3, or 4) and added, resulting in cumulative liver fat score ranging 
from 3 to 12. Liver fat score ≤4 was allocated as normal liver, score 5 – 7 was allocated as 
mild fatty liver, 8 – 10 was allocated as moderate fatty liver, and score ≥11 was allocated as 
severe fatty liver. Quality of the two operators was ensured by comparison with the senior 
radiographer, who independently scored the scans. Correlation coefficients were .97 
(p<0.001) and .86 (p<0.001) for operator 1 and 2, respectively. 
The Fenland Study 
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Questionnaire 
The general questionnaire included demographics (e.g. age, sex, ethnicity 28), medication 
use including dosages and treatment indication, and lifestyle (e.g. alcohol consumption). 
Age was divided into the following classes: lowest ≤39 years, middle 40–49 years, and 
highest ≥50 years. Alcohol consumption was reported in units a week. One unit was 
equivalent to ½ a pint of beer, 1 glass of wine, 1 single measure of spirits, and 1 glass of 
sherry, and contains approximately 8 grams of ethanol. In order to approach the usual 
ethanol threshold of 140 g/w 3, a cut-off value of ≤17 units a week (i.e. 8 grams * 17 units = 
136 grams) was used to define non-alcoholism. Due to logistic issues, some data were 
missing.    
 
METABOLIC CARDIOVASCULAR RISK ESTIMATES 
The association of liver fat content with several estimates of metabolic cardiovascular 
disease (CVD) risk was studied. Both the NCEP ATP ΙΙΙ definition 29, and IDF definition 30 
of the metabolic syndrome (MetS) were studied. In addition, the standardized sex-specific 
cumulative Z-score, and the standardized sex-specific cumulative Z-score by Franks et al. 31 
were studied. Finally, the association with the 10-year Framingham risk score 32 was 
investigated. Details of these metabolic CVD risk estimates are shown in schematic form 
by appendix Ι.  
 
STATISTICAL ANALYSIS 
Differences between two groups were compared using the unpaired t-test or Mann-Whitney 
U-test. Differences between more groups were tested by one-way ANOVA or Kruskal-
Wallis test. Differences of dichotomous variables between two or more groups were tested 
using Chi-square test. Association of variables was estimated by Pearson’s rho (r), 
explained variance (R2), and/or receiver operating characteristic curve (ROC-curve) with 
area under the curve (AUC). Logistic regression analysis was used to find variables that 
significantly predict the presence of FLD. To establish the independent predictors, 
univariately significant variables were explored in a multiple logistic regression model. 






Overall prevalence    
Figure ІІ shows results on distribution of liver fat score and prevalence of FLD. Median 
liver fat score was 4, with a mean of 4.67 (95% confidence interval 4.54 – 4.79). Of all 762 
participants, 469 had normal liver (61.5%), 208 had mild fatty liver (27.3%), 85 had 
moderate fatty liver (11.2%), and none of the participants had severe fatty liver. Thus, 293 
participants had elevated hepatic fat content due to any etiology, corresponding to a FLD 
prevalence of 38.5%. Table І shows the characteristics of the study population, stratified for 
liver fat category. 
Prevalence in non-alcoholics and alcoholics    
Of all 459 participants with low alcohol consumption, 319 had normal liver (69.5%), 96 
had mild fatty liver (20.9%), and 44 had moderate fatty liver (9.6%). These results 
correspond with a NAFLD prevalence of 30.5%. Of all 76 participants with high alcohol 
consumption, 40 had normal liver (52.6%), 23 had mild fatty liver (30.3%), and 13 had 
moderate fatty liver (17.1%). These results correspond with an AFLD prevalence of 47.4%. 
Sex    
Figure ІІb shows that liver fat significantly differs between sexes (p<0.001). Of all 242 
men, 108 (44.6%) had a fatty liver. Of all 337 women, 75 (22.3%) had a fatty liver. 
Because of this large sex difference all further analysis were performed for men and women 
separately.  
Alcohol    
Figure ІІc shows the prevalence’s of AFLD and NAFLD. Of all 169 non-alcoholic men, 29 
(46.2%) had a fatty liver. Of all 59 alcoholic men, also 29 (49.2%) had a fatty liver. Of all 
290 non-alcoholic women, 62 (21.4%) had a fatty liver. Of all 17 alcoholic women, 7 
(41.2%) had a fatty liver. 
Age class    
With increasing age class, FLD increases as well with p<0.05 for both men and women. In 
men, FLD prevalence was 27.5%, 46%, and 53.8% in the lowest, middle, and highest age 
class, respectively. In women, FLD prevalence was 13.2%, 20.3%, and 30.5% in the 
lowest, middle, and highest age class, respectively. 






a. Distribution of liver fat score  
≤4, normal; 5-7, mild; 8-10, moderate; ≥11, severe 
b. Prevalence stratified for sex 







c. Prevalence stratified for alcohol use 
p=ns for both men nor women, by chi-square test 
Figure ІІ. Distribution and prevalence of liver fat by ultrasound, including stratification for 
sex and alcohol use.  
ns, not significant. 
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Table І. Characteristics of the study population, stratified for liver fat category 
 Normal Mild Moderate P Total 
Women (w/m, w%)  (262/134) 66.2  (49/75) 39.5  (26/33) 44.1 p<.001 (337/242) 58.2  




- Asian or Asian British 
- Black or Black British 


























Household income  












Test site (n)  











Height (cm) 168.8 (8.9) 171 (9.7) 171 (9.5) p<.05 169.5 (9.2) 
Weight (kg) 69.3 (12.2) 83.9 (12.9) 96 (17) p<.001 75.2 (15.8) 
BMI (kg/ m2) 24.2 (3.3) 28.7 (3.5) 31.5 (24.1–49.4) p<.001 25.4 (17.3–49.4) 
Waist (cm)  83.9 (10.0) 97.3 (9.8) 108.0 (11.2) p<.001 89.2 (13.1) 
Hip (cm) 99.6 (7.5) 106.4 (7.3) 114.8 (11.3) p<.001 102.6 (9.4) 
WHR  .8 (.1) .9 (.1) .9 (.1) p<.001 .9 (.1) 
SBP (mmHg) 117.4 (14.2) 126.6 (15.4) 128.9 (12.7) p<.001 120.6 (15.0) 
DBP (mmHg) 70.9 (9.3) 77.6 (10.4) 81.5 (9.2) p<.001 73.4 (10.2) 
Liver fat score 3 (3–4) 6 (5–7) 8 (8–10) p<.001 4 (3–10) 
Glucose (mmol/L)  4.7 (3.4–13.1) 4.9 (3.7–10.3) 5.1 (4.2–16.9) p<.001 4.7 (3.4–16.9) 
Triglycerides (mmol/L) .8 (.2–5.8) 1.2 (.3–8.8) 1.8 (.8) p<.001 .9 (.2–8.8) 
HDL cholesterol (mmol/L) 1.6 (.4) 1.3 (.7–3) 1.3 (.3) p<.001 1.6 (.4) 
Total cholesterol (mmol/L) 5.2 (.9) 5.5 (1.2) 5.8 (1.2) p<.001 5.3 (1.1) 
Total/ HDL cholesterol (mmol/L) 3.1 (1.7–8.6) 4 (1.3) 4.7 (1.4) p<.001 3.4 (1.7–9.0) 
ALT (U/L) 21 (7–135) 29.5 (7–89) 37 (4–108) p<.001 24 (4–135) 
GGT (U/L)  21 (9–433) 31.5 (10–324) 38 (17–176) p<.001 23 (9–433) 
Bilirubin (Umol/L)  9 (2–44) 9 (3–27) 10.4 (5.2) p=ns 9 (2–44) 
Alkaline Phosphatase (U/L) 71 (19.2) 78 (28–205) 83.9 (22.7) p<.001 74.5 (20.9) 
Albumin (G/L) 41.9 (2.8) 42.3 (2.9) 41.2 (3.1) p<.05 41.9 (2.9) 
Calcium (mmol/L) 2.2 (1.5–2.5) 2.2 (.1) 2.2 (.1) p<.05 2.2 (1.5–2.5) 
Alcohol status (n)  











Alcohol status (n) 
- non-alcoholic; ≤17 units per week 















Alcohol units a week  5 (0–52) 6 (0–60) 4 (0–67) p=ns 5 (0–67) 
Smoking status (n) 











Units in cigarette equivalents a day  10 (0 – 40) 10.9 (8.0) 14.8 (8.2) p<.05 11.3 (8.1) 
On any medication (y/n, y%) 141/252 (35.9) 52/68 (43.3) 31/28 (52.5) p<.001 224/348 (39.2) 
On lipid medication (n) * 









Data represent mean (sd) when normal distribution, median (min-max) when skewed distribution, or percentage 
when dichotomous. *, as specified in appendix Ι; ALT, alanine aminotransferase; GGT, gamma glutamyl 
aminotransferase; m, men; ns, not significant; w, women. 
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AGREEMENT OF LIVER FAT AND AMINOTRANSFERASES 
ALT correlated significantly with liver fat score in both men (r=.37 with p<0.001) and 
women (r=.36 with p<0.001). Explained variances were 13.4% in men and 12.9% in 
women. Also, GGT correlated significantly with liver fat score in both men (r=.18 with 
p<0.01) and women (r=.37 with p<0.001). Explained variances were 3.2% in men and 













































































1 – Specificity (‘false positives’)
 
a. ALT 
In men, the ROC curve of ALT has an AUC of .693. 
Optimum cut-off value is 25 (i.e. ≤25, >25), with SE 
87%, SP 41%, PPV 54.3%, and NPV 79.7%. 
In women, the ROC curve of ALT has an AUC of .681. 
Optimum cut-off value is 20 (i.e. ≤20, >20), with SE 
73.3%, SP 61%, PPV 35.3%, and NPV 88.8%. 
b. GGT 
In men, the ROC curve of GGT has an AUC of .721. 
Optimum cut-off value is 36 (i.e. ≤36, >36), with SE 
56.5%, SP 76.1%, PPV 65.6%, and NPV 68.5%. 
In women, the ROC curve of GGT has an AUC of .713. 
Optimum cut-off value is 32 (i.e. ≤32, >32), with SE 
40%, SP 92.3%, PPV 60%, and NPV 84.2%. 
Figure ІІІ. ROC curves of ALT and GGT on diagnosis of fatty liver 
, men; , women. 
AUC, area under the curve; NPV, negative predictive value; PPV, positive predictive value; 
ROC, receiver operating characteristic; SE, sensitivity; SP, specificity. 
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ASSOCIATES OF FATTY LIVER  
BMI class, alcohol class and medication  
Figure ІV shows associations of BMI class, alcohol class and medication use with liver fat 
score and ALT and GGT. In both men and women, an increase in BMI class is associated 
with an increase in liver fat category, ALT, and GGT (p<0.001 for all). In men, an increase 
in alcohol class is not associated with liver fat score and ALT (p=ns for both), whereas it is 
associated with an increase in GGT (p<0.001). In women, an increase in alcohol class is 
associated with an increase in liver fat score (p<0.05), whereas it is not associated with 
ALT and GGT (p=ns for both). In men, medication use of any kind is associated with an 
increase in liver fat score (p<0.001), an increase in ALT (p<0.01), and an increase in GGT 
(p<0.001). In women, medication use of any kind is not associated with liver fat score, 
ALT, and GGT (p=ns for all). 
 
PREDICTORS OF FATTY LIVER 
Table ІІ shows the results of univariate and multiple logistic regression analysis on the 
presence of FLD. By multiple logistic regression analysis, only BMI (p<0.05, OR 1.3) was 
significantly associated in men, and BMI (p<0.001, OR 1.6), waist circumference (p<0.01, 
OR 1.1), and hip circumference (p<0.01, OR .9) were significantly associated in women. 
Chapter 2. 
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 p<0.001 for both men and women, by 
Kruskal-Wallis test 
p<0.001 for both men and women, by Kruskal-
Wallis test 
p<0.001 for both men and women, by Kruskal-
Wallis test 
a. BMI class 
   
 p=ns for men and p<0.05 for women, by 
Kruskal-Wallis test 
 
p=ns for both men and women, by Kruskal-
Wallis test 
 p<0.001 for men and p=ns for women, by 
Kruskal-Wallis test 
b. Alcohol class  
   
 p<0.001 for men and p=ns for women, by 
Mann-Whitney U test 
 
p<0.01 for men and p=ns for women, by Mann-
Whitney U test 
 p<0.001 for men and p=ns* for women, by 
Mann-Whitney U test 
c. Medication use 
Figure ІV. Associations of BMI class, alcohol class, and medication use 
with liver fat score, ALT and GGT, in the population with liver fat scores  
, men; , women. 
BMI class: 1, BMI≤18.49; 2, BMI 18.5–24.99; 3, BMI 25–29.99; 4, BMI 30–34.99.  
Alcohol class: 1, ≤17 units/week; 2, 18–34 units/week; 3, 35–51 units/week; 4, 52–68 
units/week. 
*, borderline significant (p<0.1). 
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Alcohol units a week 
Smoking units a day& 











































































































































Alcohol units a week 
Smoking units a day& 




































































































































#Dependent variable: normal or fatty liver; *, borderline significant (p<0.1); &, cigarette 
equivalents a day.  
B, logistic regression coefficient; CI, confidence interval; ExpB, odds ratio; ns, not 
significant. 
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ASSOCIATIONS OF LIVER FAT CATEGORY, ALT QUINTILE AND GGT QUINTILE 
WITH SEVERAL CARDIOVASCULAR RISK ESTIMATES 
Figures V shows associations of liver fat category, ALT quintile, and GGT quintile with 
several CVD risk estimates, in the population with liver fat scores. In both men and women, 
an increase in liver fat category is associated with an increase in the number of MetS ATP 
III components, the number of MetS IDF components, the MetS Z-score (p<0.001 for all), 
and 10-year Framingham CVD risk (p=0.001 for men, p<0.001 for women). In men, an 
increase in ALT quintile is associated with an increase in the number of MetS ATP III 
components, the number of MetS IDF components, and the MetS Z-score (p<0.001 for all 
three), but not with 10-year Framingham CVD risk (p=ns). In women, an increase in ALT 
quintile is associated with an increase in the number of MetS ATP III components 
(p<0.001), the number of MetS IDF components (p<0.01), the MetS Z-score (p<0.001), and 
10-year Framingham CVD risk (p<0.01). In both men and women, an increase in GGT 
quintile is associated with an increase in the number of MetS ATP III components, the 
number of MetS IDF components, the MetS Z-score (p<0.001 for all three/six), and 10-year 
Framingham CVD risk (p<0.01 for men, p<0.001 for women). Results for the Z-score by 
Franks et al. (data not shown) were similar to the regular Z-score. 
ROC curves of liver fat, ALT, and GGT on diagnosis of the metabolic syndrome 
Figure VІ shows ROC curves of liver fat, ALT, and GGT for diagnosis of the MetS ATP 
III. The figure shows that liver fat by ultrasound has more diagnostic value than ALT and 
GGT. Results for the MetS IDF were similar (data not shown). 
 
PREVALENCE OF METABOLIC SYNDROME COMPONENTS PER LIVER FAT 
CATEGORY 
Figures VІІ shows prevalence of the number of MetS ATP III components per liver fat 
category. With increasing liver fat category the number of MetS ATP III components 
increased as well. Of all participants with normal liver, most participants had no 
component. Of all participants with mild fatty liver, most had 1 (women) or 2 (men) 
components. Of all participants with moderate fatty liver, most participants had 3 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The prevalence of FLD due to any etiology we found in the population aged 30 to 58 years 
is 38.5%. Men contributed to this high prevalence the most (p<0.001). Importantly, this 
high prevalence was found in a relatively healthy general population based study 
population (e.g. people with known diabetes excluded). Additionally, BMI in the total 
population (median 26.3 with range 16.9–63.5 kg/m2) was higher than BMI in the 
population with liver fat scores (median 25.4 with range 17.3– 49.4 kg/m2). Therefore, the 
true prevalence of FLD in East Anglia may likely be even higher than the already striking 
prevalence reported in this paper.  
An increase in liver fat category was associated with an increase in the number of ATP III 
MetS components, the number of IDF MetS components, the MetS Z-score, and 10-year 
Framingham CVD risk (figure V).  
 
AGREEMENT OF AMINOTRANSFERASES AND LIVER FAT 
Aminotransferases ALT and GGT correlated with liver fat, which was also found in other 
imaging studies. ALT correlates with liver fat by magnetic resonance spectroscopy in non-
diabetic, non-alcoholic, apparently healthy men (r=0.44–0.62, p<0.0001) and women 
(r=0.39–0.49, p<0.0001) 33
, 34. The present study is also in line with recently proposed 
lowering of ALT cut-off values 27, in order to achieve increased overall diagnostic value for 
FLD. A study in blood donors suggested lowering ALT cut-off values from 40 to 30 for 
men and from 30 to 19 for women 27. The present study suggests optimal ALT cut-off 
values of 25 for men and 20 for women (figure ІІІ). Further lowering cut-off values for 
aminotransferases, e.g. for screening studies, will increase sensitivity but cause a decreased 
specificity as a consequence.  
Additionally, this study suggests that both ALT and GGT are inferior to liver fat by 
ultrasound regarding diagnosing the MetS ATP III (and IDF) as shown in figure VІ.  
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THE PRESENT STUDY COMPARED TO OTHER STUDIES 
FLD prevalence compared to other prevalences 
This is the first general population based study on imaging-determined FLD in the UK. Of 
all Western general population based studies on FLD using imaging modalities, 
chronologically organized in table ІІІ, the present study revealed the highest FLD 
prevalence. Reported overall prevalence’s were 29.9% by the SHIP study 20, 31% by the 
DHS study (33% in Whites) when using a cut-off value based upon the 95th percentile of a 
low risk population 21, 22, 27.4% by the EMIL study 23, and 38.5% in the present Fenland 
Study. In the FIN-D2D study using magnetic resonance spectroscopy, a substantial 
difference in prevalence of AFLD (7%) and prevalence of NAFLD (21%) was found, 
whereas BMI and components of the MetS were similar in both groups. Alcohol is a major 
risk factor for advanced FLD, and compared to NAFLD, AFLD is more associated with 
advanced FLD 35
, 36. It is known that, while the FLD spectrum progresses to its advanced 
stages, liver fat content decreases 5
, 37. Thus theoretically, the AFLD group could include 
more advanced FLD cases which are characterised by low liver fat content, likely causing 
magnetic resonance spectroscopy to miss advanced AFLD cases. As cirrhosis (an advanced 
stage of FLD) appears as bright liver by ultrasound, advanced FLD cases are most likely 
included in the present Fenland Study. 
Ultrasonography method compared to other ultrasonography methods  
In previous old studies, FLD was scored on a semi-quantitative scale as normal, mild, 
moderate, or severe 38, 39. When compared with histology, sensitivity and specificity of this 
method range from 89%–94% and 84%–93%, respectively 38, 39. In the present study, liver 
fat content was scored in a cumulative fashion, followed by allocation to liver fat 
categories, similar to the scoring system by Hamaguchi et al. (2007) 40. A differences 
between the two scoring systems is that, as based on older studies 38, 39, Hamaguchi et al. 
considered hyperechogeneity as a mandatory component for diagnosis of FLD 40. 
Additionally, the authors scored attenuation on a 3-point scale (compared to the present 4-
point scale) and vessel blurring on a 2-point scale (compared to the present 4-point scale) 
40. The authors validated their method using histology in a population excluding other liver 
disease and alcoholics (total n=94, including NAFLD n=64) 40. Their method revealed an 
AUC of 0.980, a sensitivity of 91.2%–92.6%, a specificity of 100%, an intra-observer 
reliability by Cohen’s kappa of 0.95 (p<0.001) and an inter-observer reliability by Cohen’s 
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kappa of 0.95 (p<0.001) 40. It should be noted that the current used ultrasonography scoring 
method has not been validated yet.  
Study design compared to other study designs 
Besides period of data collection and imaging methods, there are other differences between 
these studies regarding study populations. Some important characteristics are included in 
table ІІІ. Although derived from the general population, the DNLS 1st-phase 18, DHS 21, 22 
and DNLS 2nd-phase 19 were strongly designed on BMI and alcohol intake 18, ethnicity 21, 22, 
and presence and absence of suspected liver disease 19. The DNLS study 18, 19 and SHIP 
study 20 excluded hepatitis and other known liver disease, whereas these were not 
determined in the DHS 21, 22 and the present Fenland Study. Another important difference 
between the present and other studies in that known diabetes mellitus is an exclusion factor 
in the present Fenland Study. 
Weaknesses of the present study 
The population with and without liver fat scores differed with respect to sex (females 
58.2% versus 53.4% respectively [p<0.05]) and BMI (median 25.4 versus 26.6 kg/m2 
respectively [p<0.001]). Analysis on the total population revealed that overall men are more 
obese than women. The median BMI of men (27 kg/m2) and women (25.6 kg/m2) in the 
total population differed significantly (p<0.001). The mean waist circumference of men 
(98.2 cm) and women (86.7 cm) differed significantly (p<0.001) as well. Despite of the 
major back log of liver fat scores compared to other data, this difference in sex and BMI 
might be attributable to difficulties in scanning obese people, i.e. mostly men, using an 
image modality 25, 26, e.g. ultrasonography 41
, 42 and magnetic resonance spectroscopy as 
well 22. In the DHS, using magnetic resonance spectroscopy, only participants fitting the 
scanner could be included 22. Besides, being sometimes not possible, the diagnostic value of 
ultrasonography is decreased in obese people as well 41
, 42.  
 
ASSOCIATES OF FATTY LIVER  
BMI class, alcohol class and medication  
BMI (notably peripheral fat depots) 43, alcohol 44, and certain drugs 44 are associated with 
the etiology of FLD. Both figure ІV and results of the logistic regression analyses (table ІІ) 
indicate that BMI is more strongly associated with liver fat by ultrasound than alcohol use. 
This was also found in the DNLS 18. However, it might be important to distinguish AFLD 
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and NAFLD as both may follow different clinical courses 35
, 36. Studies by histology 
suggest that AFLD is overall more associated with progression of liver damage, i.e. 
progression of fibrosis stage 35
, 36, which may delineate a regression of liver fat content 5
, 37. 
NAFLD is overall more associated with CVD 45, but it should be noted that even people 
with NAFLD are at increased risk for severe liver pathology 5-7. Strangely, follow-up of 
participants from the DNLS suggests that alcohol use is the most important predictor of 
both incidence and regression of fatty liver by ultrasound 46. However, theoretically this 
regression might be attributable to an increase in fibrosis stage (notably not determined by 
histology) accompanied by a decrease in liver fat content 5
, 37. The association between 
medication use and liver fat score, particularly in men (figure ІVc), suggests that the 
participants with higher liver fat score are unhealthier. Whereas in the SHIP study, 
increased medication use was largely attributable to diabetes and lipid lowering medication 
47 this is not possible in the present non-diabetic study population. Smoking was not 
associated with liver fat by ultrasound (table ІІ), as also previously found 23
, 48.  
 
CARDIOVASCULAR DISEASE RISK ESTIMATES 
This study is in line with the idea of FLD being the hepatic component of the MetS 3. The 
optimal cut-off value for diagnosis of the MetS ATP III was a liver fat score of 4 (≤4, >4), 
which corresponds with the threshold between normal liver and (mild) fatty liver. 
Additionally, liver fat was associated with the 10-year Framingham CVD risk (figure V). 
Although there is speculation about the value of the MetS for CVD risk prediction, a meta-
analysis of longitudinal studies (37 studies including 43 cohorts) revealed that participants 
with the MetS are at increased risk for incident CVD events 49.  
 
CONCLUSION 
This study shows a striking prevalence of FLD in East Anglia, particularly in men. As FLD 
is associated with several CVD risk estimates, this striking prevalence may delineate an 
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st
)/
2
 
2
. 
Z
-d
y
sl
ip
id
ea
m
ia
: 
(T
G
s+
in
v
er
te
d
 H
D
L
)/
2
 
3
. 
Z
-h
y
p
er
te
n
si
o
n
: 
(S
B
P
+
D
B
P
)/
2
, 
 
4
. 
Z
-g
lu
co
se
: 
G
lu
co
se
 
A
ll
 Z
-s
co
re
s 
w
er
e 
st
an
d
ar
d
iz
ed
 u
si
n
g
: 
Ζ
Ζ
−
Ζ
=
Ζ
σ
µ
F
ra
n
k
s
 (
fo
r 
m
al
es
 a
n
d
 f
em
al
es
 s
ep
ar
at
el
y
).
 A
ll
 
in
d
iv
id
u
al
 Z
-F
ra
n
k
s 
w
er
e 
ad
d
ed
 t
o
 f
o
rm
 a
 c
u
m
u
la
ti
v
e 
Z
-F
ra
n
k
s 
sc
o
re
 
1
0
-y
ea
r 
F
R
S
 3
2
 
1
. 
A
g
e;
 2
. 
T
o
ta
l-
C
; 
3
. 
H
D
L
-C
; 
 
4
. 
S
B
P
 w
it
h
/w
it
h
o
u
t 
an
ti
-h
y
p
er
te
n
si
v
es
*
*
; 
 
5
. 
S
m
o
k
er
 (
y
es
/n
o
);
 6
. 
D
ia
b
et
ic
 (
y
es
/n
o
) 
A
ll
o
ca
ti
o
n
 o
f 
p
o
in
ts
 a
cc
o
rd
in
g
 t
o
 D
’A
g
o
st
in
o
 e
t 
al
. 
(2
0
0
8
);
 
ta
b
le
s 
5
 a
n
d
 7
 3
2
 
S
ig
n
s:
 #
, 
th
e 
N
C
E
P
 A
T
P
ΙΙ
Ι 
M
et
S
 i
s 
‘d
ia
g
n
o
se
d
’ 
if
 a
t 
le
as
t 
th
re
e 
co
m
p
o
n
en
ts
 a
re
 p
re
se
n
t;
 #
#
, 
th
e 
ID
F
 M
et
S
 i
s 
‘d
ia
g
n
o
se
d
’ 
if
 e
le
v
at
ed
 w
ai
st
 p
lu
s 
at
 l
ea
st
 t
w
o
 o
th
er
 c
o
m
p
o
n
en
ts
 a
re
 p
re
se
n
t;
 *
, 
B
N
F
-c
o
d
e:
 2
.1
2
 (
li
p
id
-r
eg
u
la
ti
n
g
 d
ru
g
s,
 
i.
e.
 s
ta
ti
n
s 
an
d
 f
ib
ra
te
s)
; 
*
*
, 
B
N
F
-c
o
d
es
: 
2
.4
 (
b
et
a-
ad
re
n
o
re
ce
p
to
r 
b
lo
ck
in
g
 d
ru
g
s)
, 
2
.5
.1
 (
v
as
o
d
il
at
o
r 
an
ti
h
y
p
er
te
n
si
v
e 
d
ru
g
s)
, 
2
.5
.2
 (
ce
n
tr
al
ly
 a
ct
in
g
 a
n
ti
h
y
p
er
te
n
si
v
e 
d
ru
g
s)
, 
2
.5
.4
 (
al
p
h
a-
ad
re
n
o
re
ce
p
to
r 
b
lo
ck
in
g
 d
ru
g
s)
, 
2
.5
.5
.1
 
(a
n
g
io
te
n
si
n
-c
o
n
v
er
ti
n
g
 e
n
zy
m
e 
in
h
ib
it
o
rs
),
 2
.5
.5
.2
 (
an
g
io
te
n
si
n
-I
I-
re
ce
p
to
r 
an
ta
g
o
n
is
t)
, 
2
.6
.1
 (
n
it
ra
te
s)
, 
2
.6
.2
 (
ca
lc
iu
m
-c
h
an
n
el
 b
lo
ck
er
s)
, 
2
.6
.3
 (
p
o
ta
ss
iu
m
 c
h
an
n
el
 a
ct
iv
at
o
rs
),
 a
n
d
 2
.6
.4
 (
p
er
ip
h
er
al
 v
as
o
d
il
at
o
rs
 a
n
d
 r
el
at
ed
 d
ru
g
s)
. 
A
b
b
re
v
ia
ti
o
n
s:
 B
M
I,
 b
o
d
y
 m
as
s 
in
d
ex
 (
k
g
/m
2
);
 B
N
F
, 
B
ri
ti
sh
 N
at
io
n
al
 F
o
rm
u
la
ry
; 
C
-c
h
o
le
st
er
o
l;
 D
B
P
, 
d
ia
st
o
li
c 
b
lo
o
d
 p
re
ss
u
re
; 
(f
),
 c
u
t-
o
ff
 v
al
u
e 
fo
r 
fe
m
al
es
; 
F
R
S
, 
F
ra
m
in
g
h
am
 r
is
k
 s
co
re
; 
H
D
L
, 
h
ig
h
 d
en
si
ty
 l
ip
o
p
ro
te
in
; 
ID
F
, 
in
te
rn
at
io
n
al
 d
ia
b
et
es
 f
ed
er
at
io
n
; 
(m
),
 c
u
t-
o
ff
 v
al
u
e 
fo
r 
m
al
es
; 
M
et
S
, 
m
et
ab
o
li
c 
sy
n
d
ro
m
e;
 N
C
E
P
 A
T
P
ΙΙ
Ι,
 N
at
io
n
al
 c
h
o
le
st
er
o
l 
ed
u
ca
ti
o
n
 p
ro
g
ra
m
. 
A
d
u
lt
 t
re
at
m
en
t 
p
an
el
 3
; 
S
B
P
, 
sy
st
o
li
c 
b
lo
o
d
 p
re
ss
u
re
; 
T
G
, 
tr
ig
ly
ce
ri
d
es
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